PE20091057A1 - Antagonistas del receptor mineralcorticoide y metodos de uso - Google Patents
Antagonistas del receptor mineralcorticoide y metodos de usoInfo
- Publication number
- PE20091057A1 PE20091057A1 PE2008002008A PE2008002008A PE20091057A1 PE 20091057 A1 PE20091057 A1 PE 20091057A1 PE 2008002008 A PE2008002008 A PE 2008002008A PE 2008002008 A PE2008002008 A PE 2008002008A PE 20091057 A1 PE20091057 A1 PE 20091057A1
- Authority
- PE
- Peru
- Prior art keywords
- oxepin
- iliden
- dibenzo
- methyl
- mineralcorticoid receptor
- Prior art date
Links
- 239000002395 mineralocorticoid Substances 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
- -1 IMIDAZOL-2 (3H) -YLIDENE Chemical class 0.000 abstract 1
- XZMCDFZZKTWFGF-NJFSPNSNSA-N aminoformonitrile Chemical compound N#[14C]N XZMCDFZZKTWFGF-NJFSPNSNSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 230000002107 myocardial effect Effects 0.000 abstract 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1477607P | 2007-12-19 | 2007-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091057A1 true PE20091057A1 (es) | 2009-07-20 |
Family
ID=40430143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008002008A PE20091057A1 (es) | 2007-12-19 | 2008-12-02 | Antagonistas del receptor mineralcorticoide y metodos de uso |
Country Status (33)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
| WO2009076747A1 (en) | 2007-12-19 | 2009-06-25 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| JP5570536B2 (ja) * | 2009-03-12 | 2014-08-13 | イーライ リリー アンド カンパニー | 鉱質コルチコイド受容体アンタゴニストおよび使用方法 |
| CA2796307A1 (en) | 2010-05-10 | 2011-11-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| JP6180930B2 (ja) | 2010-06-16 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 創傷治癒過程における再上皮化を刺激するための方法及び組成物 |
| CN102060670A (zh) * | 2011-01-04 | 2011-05-18 | 常州大学 | 一种2-溴-6-氟苯甲醇的制备方法 |
| AP2015008843A0 (en) | 2013-05-02 | 2015-11-30 | Pfizer | Imidazo-triazine derivatives as pde10 inhibitors |
| AR099416A1 (es) | 2014-02-28 | 2016-07-20 | Lilly Co Eli | Terapia combinada para la hipertensión resistente |
| SI3160948T1 (sl) | 2014-06-30 | 2020-06-30 | Astrazeneca Ab | Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida |
| CA2963683A1 (en) * | 2014-11-21 | 2016-05-26 | Eli Lilly And Company | 1,2-benzothiazole compounds for the treatment of kidney disorders |
| US20180280414A1 (en) | 2015-10-13 | 2018-10-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| MX391602B (es) * | 2016-09-24 | 2025-03-21 | Novo Nordisk As | Composicion farmaceutica con antagonista del receptor de mineralocorticoides y su uso |
| WO2021180818A1 (en) | 2020-03-11 | 2021-09-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
| WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072756A (en) | 1973-05-17 | 1978-02-07 | Sandoz Ltd. | Tricyclo piperidino ketones and soporific compositions thereof |
| SE426341C (sv) * | 1980-02-14 | 1985-09-23 | Fagersta Ab | Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser |
| DE3730258A1 (de) | 1986-09-10 | 1988-04-07 | Canon Kk | Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung |
| US4999363A (en) | 1988-06-09 | 1991-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| GB8914061D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| US5378701A (en) | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
| ZA9811898B (en) | 1997-12-29 | 2000-06-28 | Ortho Mcneil Pharm Inc | Anti-Inflammatory Compounds. |
| EP1154997A4 (en) | 1999-01-26 | 2002-11-04 | Dana Farber Cancer Inst Inc | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE |
| EP1448566B3 (en) * | 2001-11-21 | 2009-04-08 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| ES2308296T3 (es) | 2003-12-19 | 2008-12-01 | Eli Lilly And Company | Modulares del receptor nuclear de hormonas esteroideas triciclicas. |
| WO2005066153A1 (en) | 2003-12-19 | 2005-07-21 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| JP2008508314A (ja) | 2004-07-28 | 2008-03-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | ステロイドホルモン核内受容体のモジュレーターとしての化合物および組成物 |
| KR101368228B1 (ko) | 2004-11-10 | 2014-02-27 | 인사이트 코포레이션 | 락탐 화합물 및 약제로서의 이의 용도 |
| AP2527A (en) | 2006-10-31 | 2012-12-06 | Pfizer Prod Inc | Pyrazoline compounds as mineralocorticoid receptorantagonists |
| EP2142194A1 (en) | 2007-03-29 | 2010-01-13 | N.V. Organon | Mineralocorticoid receptor antagonists |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| CA2711887A1 (en) | 2008-01-25 | 2009-07-30 | Arena Pharmaceuticals, Inc. | Dihydro-1h-pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists |
| JP5570536B2 (ja) | 2009-03-12 | 2014-08-13 | イーライ リリー アンド カンパニー | 鉱質コルチコイド受容体アンタゴニストおよび使用方法 |
-
2008
- 2008-12-02 PE PE2008002008A patent/PE20091057A1/es not_active Application Discontinuation
- 2008-12-02 TW TW097146779A patent/TWI431010B/zh not_active IP Right Cessation
- 2008-12-03 AR ARP080105263A patent/AR069554A1/es unknown
- 2008-12-03 CL CL2008003600A patent/CL2008003600A1/es unknown
- 2008-12-09 RS RS20120541A patent/RS52594B/sr unknown
- 2008-12-09 AU AU2008343524A patent/AU2008343524B2/en not_active Ceased
- 2008-12-09 MX MX2010006911A patent/MX2010006911A/es active IP Right Grant
- 2008-12-09 SI SI200830852T patent/SI2235007T1/sl unknown
- 2008-12-09 PT PT88668355T patent/PT2235007E/pt unknown
- 2008-12-09 MY MYPI20102867 patent/MY150474A/en unknown
- 2008-12-09 BR BRPI0820805-0A patent/BRPI0820805A2/pt not_active IP Right Cessation
- 2008-12-09 UA UAA201007627A patent/UA100131C2/uk unknown
- 2008-12-09 NZ NZ586300A patent/NZ586300A/en not_active IP Right Cessation
- 2008-12-09 CN CN200880121527.2A patent/CN101903377B/zh not_active Expired - Fee Related
- 2008-12-09 DK DK08866835.5T patent/DK2235007T3/da active
- 2008-12-09 HR HRP20120916AT patent/HRP20120916T1/hr unknown
- 2008-12-09 EP EP08866835A patent/EP2235007B1/en active Active
- 2008-12-09 PL PL08866835T patent/PL2235007T3/pl unknown
- 2008-12-09 US US12/330,539 patent/US7994164B2/en not_active Expired - Fee Related
- 2008-12-09 WO PCT/US2008/085997 patent/WO2009085584A1/en not_active Ceased
- 2008-12-09 JP JP2010539618A patent/JP5562866B2/ja not_active Expired - Fee Related
- 2008-12-09 EP EP12185389.9A patent/EP2537845B1/en active Active
- 2008-12-09 ES ES08866835T patent/ES2396605T3/es active Active
- 2008-12-09 EA EA201070762A patent/EA017668B1/ru not_active IP Right Cessation
- 2008-12-09 CA CA2710409A patent/CA2710409C/en not_active Expired - Fee Related
- 2008-12-09 ES ES12185389.9T patent/ES2459318T3/es active Active
- 2008-12-09 KR KR1020107013601A patent/KR101254382B1/ko not_active Expired - Fee Related
-
2010
- 2010-06-14 IL IL206353A patent/IL206353A/en not_active IP Right Cessation
- 2010-06-14 MA MA32909A patent/MA31910B1/fr unknown
- 2010-06-15 ZA ZA2010/04257A patent/ZA201004257B/en unknown
- 2010-06-16 CO CO10072532A patent/CO6300953A2/es not_active Application Discontinuation
- 2010-06-17 DO DO2010000185A patent/DOP2010000185A/es unknown
- 2010-06-17 EC EC2010010266A patent/ECSP10010266A/es unknown
- 2010-06-17 GT GT201000179A patent/GT201000179A/es unknown
- 2010-06-18 TN TN2010000292A patent/TN2010000292A1/fr unknown
-
2012
- 2012-07-17 EC ECSP12012048 patent/ECSP12012048A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| PE20081467A1 (es) | Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk) | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| JP2011507868A5 (enExample) | ||
| PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
| PE20081659A1 (es) | Agonistas de gpcr | |
| PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20110679A1 (es) | Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20070187A1 (es) | Moduladores de lxr basados en pirazol | |
| PE20081884A1 (es) | Inhibidores heterociclicos de la aspartil proteasa | |
| PE20091042A1 (es) | Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841 | |
| PE20120546A1 (es) | Inhibidores del virus de la hepatitis c | |
| PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20070585A1 (es) | Derivados de sulfonamida como activadores de glucoquinasa | |
| PE20120578A1 (es) | Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| PE20110067A1 (es) | Derivados de piperidina como inhibidores de renina | |
| PE20080677A1 (es) | Inhibidores de pirrolotriazina cinaza | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20090875A1 (es) | Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| CO6220853A2 (es) | Derivados de pentafluorotiobenzamido acetonitrilo como agentes antiparasitarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |